Ionis Pharmaceuticals: A letter to the Angelman syndrome community.
Ionis addresses community questions following the ASPIRE trial results, reaffirming its commitment to obudanersen (ION582) through the HALOS, REVEAL, and CHAMPION trials
Update on CHAMPION, Phase 3 clinical trial of ION582 (obudanersen)
Ionis shares an update on CHAMPION, its Phase 3 trial for ION582 (obudanersen) in Angelman syndrome due to UPD or ICD, with eligibility details now on clinicaltrials.gov.
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Ionis completes enrollment for Cohort 1 of the pivotal Phase 3 REVEAL study evaluating obudanersen for Angelman syndrome. Cohort 2 screening continues for ages 18–50.
An Update on the ION582 clinical development program including HALOS, REVEAL, and CHAMPION Trials
Ionis shares an update on ION582 development, covering progress across the HALOS, REVEAL, and newly announced CHAMPION trials expanding research into additional AS genotypes.
Ionis Receives Breakthrough Therapy Designation for ION582 in Angelman Syndrome
Ionis Pharmaceuticals’ ION582 has received FDA Breakthrough Therapy Designation for Angelman syndrome, a status reserved for drugs showing substantial improvement over existing treatments.
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
Ionis Pharmaceuticals has dosed the first participant in its global Phase 3 REVEAL trial, evaluating the safety and efficacy of ION582 as a potential treatment for Angelman syndrome.
IONIS REVEAL Phase 3 Clinical Trial Update
The next chapter for ION582 is here: Ionis’ Phase 3 REVEAL trial is now listed, marking an important step toward a potential treatment for Angelman syndrome. Join FAST, ASF, and Ionis to learn what comes next.
Ionis Pharmaceuticals releases information on their planned phase 3 clinical trial for Angelman syndrome
Ionis Pharmaceuticals announces ION582 will advance into Phase 3, called REVEAL, with details to be presented at the FAST Global Science Summit on November 9th.
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Ionis Pharmaceuticals issued a press release today regarding their Phase 1/2a HALOS clinical trial of ION582 for individuals living with Angelman syndrome. Join the livestream on July 24th starting at 3:10pm ET where Ionis and other industry leaders will present information to parents and caregivers at the Angelman Syndrome Foundation (ASF) Family Conference. You can […]
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
Exciting news for the Angelman syndrome community! Ionis’ Angelman syndrome program, ION582, has just shared positive preliminary results from the Phase 1/2a HALOS clinical trial. Ionis will be providing an update at the upcoming Angelman Syndrome Foundation meeting in July, which will be streamed for those who cannot attend. Read the community letter from Ionis […]